Molecular Diagnostics For Emerging Infectious Diseases Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Molecular Diagnostics for Emerging Infectious Diseases Market Report is Segmented by Product Type (Instruments, and More), Technology (PCR, Mass Spectrometry, and More), Sample Type (Respiratory Swabs, and More), Pathogen Type (Viral, and More), Application (Pathogen Detection, and More), End-User (Hospitals & Clinics, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Molecular Diagnostics For Emerging Infectious Diseases Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Molecular Diagnostics For Emerging Infectious Diseases Market with other markets in Healthcare Industry

Molecular Diagnostics For Emerging Infectious Diseases Market Analysis by Mordor Intelligence

The molecular diagnostics for emerging infectious disease market size is USD 4.06 billion in 2025 and is projected to reach USD 5.37 billion by 2030, reflecting a 5.71% CAGR. Sustained government spending on pandemic-preparedness programs keeps demand stable even as the COVID-19 surge recedes. Uptake of syndromic panels, non-invasive sample collection, and data-rich reporting tools pushes laboratories toward platform-integrated solutions. CRISPR-enabled assays and rapid next-generation sequencing shorten time-to-result, while wastewater surveillance broadens the testing footprint. Strong patent activity and cross-sector partnerships underscore the need for flexible systems that can pivot quickly to new threats.

Key Report Takeaways

  • By product type, reagents and kits held 66.51% of the molecular diagnostics for emerging infectious disease market share in 2024, whereas software and services are advancing at a 13.25% CAGR through 2030.
  • By technology, PCR led with 40.53% revenue share in 2024; CRISPR-based platforms are forecast to expand at a 14.85% CAGR to 2030. 
  • By sample type, respiratory swabs accounted for 44.63% of the molecular diagnostics for emerging infectious disease market size in 2024, while saliva and oral fluids show a 13.87% CAGR outlook.
  • By pathogen type, viral segment accounted for 64.32% share of the market size in 2024; novel / unknown pathogens are expected to climb at 18.27% CAGR through 2030.
  • By end user, hospitals & clinics held 42.21% revenue share in 2024, whereas public health agencies are forecast to grow at 13.17% CAGR between 2025 and 2030.
  • By application, pathogen detection led with 75.32% of the market share in 2024, while syndromic panels are projected to compound at 15.17% CAGR to 2030.
  • By geography, North America captured 39.32% share in 2024; Asia-Pacific is growing fastest at a 10.17% CAGR through 2030.

Segment Analysis

By Product Type: Services accelerate platform integration

Reagents and kits commanded 66.51% of the molecular diagnostics for emerging infectious disease market in 2024. Software and services, though smaller, are rising at a 13.25% CAGR as laboratories prefer turnkey packages that fuse testing hardware with analytics dashboards and cyber-security layers. 

Laboratories adopting the BIOFIRE FILMARRAY TORCH cut hands-on time to minutes while securing automated quality control. Vendors earn recurring revenue by bundling consumables, informatics, and remote support into subscription contracts that ease capital pressure and ensure instrument uptime.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: CRISPR transforms detection

PCR retained 40.53% share in 2024, yet CRISPR assays are scaling at 14.85% CAGR on the strength of sequence-agnostic detection and portable formats. The molecular diagnostics for emerging infectious disease market size for CRISPR solutions is forecast to expand quickly as regulatory clearances accumulate. 

Isothermal methods such as LAMP bridge resource gaps, while next-generation sequencing and nanopore workflows provide full genomic snapshots for surveillance. Combined, these alternatives chip away at PCR’s dominance and encourage laboratories to diversify portfolios for speed, breadth, and resilience.

By Sample Type: Non-invasive collection gains ground

Respiratory swabs delivered 44.63% of the molecular diagnostics for emerging infectious disease market size in 2024. Saliva and oral fluids, growing at 13.87% CAGR, improve patient comfort and reduce exposure risk for healthcare staff. 

Wastewater testing adds community-level insight, detecting pathogen trends before clinical case spikes. Innovations in inhibitor removal and rapid concentration shorten processing time, widening adoption in municipal monitoring programs.

By Pathogen Type: Novel threats spur broad-spectrum assays

Viral agents held 64.32% share in 2024, yet assays for unknown pathogens are advancing fastest at 16.27% CAGR as stakeholders prioritize future-proof platforms. The molecular diagnostics for emerging infectious disease market welcomes metagenomic screens that flag unexpected organisms and resistance genes in a single run. 

Bacterial, fungal, and parasitic panels remain essential for targeted infections but see steadier growth. AI-guided primer design and adaptive bioinformatics help test makers stay ready for the next novel threat.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Syndromic panels reshape workflows

Pathogen detection made up 75.32% of revenue in 2024. Syndromic panels, however, are scaling at 15.17% CAGR by delivering 20-plus targets in under an hour and guiding therapy at first encounter. 

Hospitals gain operational efficiency, while public-health programs benefit from real-time data streams that integrate with surveillance dashboards. Resistance testing and biothreat panels expand these gains into antimicrobial stewardship and security domains.

By End-User: Public-health demand surges

Hospitals and clinics represented 42.21% of consumption in 2024, but public-health agencies are rising at a 13.17% CAGR as governments fund regional hubs and mobile labs. The molecular diagnostics for emerging infectious disease market thus leans toward high-throughput instruments able to flex from routine workflows to surge capacity during emergencies. 

Academic centers continue to drive discovery and validation, feeding novel assays into commercial channels. Diagnostic laboratories remain critical for quality assurance and large-scale testing services.

Geography Analysis

North America captured 39.32% revenue in 2024 on the back of strong reimbursement, integrated electronic records, and swift translation of R&D outputs into clinical tools. FDA rules on emergency use and LDT oversight guide quality while challenging smaller entrants. Continued public-private funding partnerships underpin steady platform upgrades.

Europe shows steady demand amid budget pressures and the implementation of IVDR. Harmonized standards lift quality, yet compliance costs favor well-capitalized suppliers. Personalized-medicine initiatives sustain high-complexity testing, and national procurement programs keep price competition tight.

Asia-Pacific posts the fastest regional CAGR of 10.17%, fueled by health-system expansion, rising awareness, and state support for biotech manufacturing. China’s investments in domestic platforms increase self-reliance, while Japan’s aging population drives sophisticated pathogen panels. India’s broad disease burden encourages hybrid models mixing centralized labs and point-of-care devices.

Molecular Diagnostics For Emerging Infectious Diseases Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The molecular diagnostics for emerging infectious disease market features moderate fragmentation. Roche, Abbott, and Thermo Fisher Scientific leverage broad menus, global channels, and regulatory depth to defend share. Service contracts and middleware analytics differentiate offers and lock in consumable revenue.

Specialists including Sherlock Biosciences and Oxford Nanopore Technologies push disruptive models such as CRISPR and portable sequencing. Larger firms respond by acquiring capabilities, exemplified by Bruker’s EUR 870 million purchase of Elitech, which widened its European footprint and infectious-disease portfolio.

Partnerships between diagnostics and pharmaceutical companies accelerate companion-diagnostic development, weaving testing into therapeutic decision paths. AI collaboration agreements shorten design cycles and tailor panels to local epidemiology, intensifying competitive dynamics without a single player dominating revenue.

Molecular Diagnostics For Emerging Infectious Diseases Industry Leaders

  1. Thermo Fisher Scientific, Inc.

  2. F. Hoffmann-La Roche Ltd

  3. Abbott Laboratories

  4. Illumina Inc.

  5. bioMérieux SA

  6. *Disclaimer: Major Players sorted in no particular order
Molecular Diagnostics for Emerging Infectious Disease Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: FDA issued draft guidance on validation requirements for in vitro diagnostic devices aimed at emerging pathogens during Section 564 emergencies, streamlining future rapid-test clearances.
  • May 2024: Bruker completed its EUR 870 million acquisition of Elitech Group, adding molecular platforms and enlarging its European base.

Table of Contents for Molecular Diagnostics For Emerging Infectious Diseases Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Surge In Outbreaks Of Zoonotic & Vector-Borne Diseases
    • 4.2.2 Acceleration Of Pandemic-Preparedness Funding Pipelines
    • 4.2.3 Rapid-Turnaround NGS & Digital PCR Platforms
    • 4.2.4 Decentralized Point-Of-Care (POC) Deployment In Low-Resource Settings
    • 4.2.5 Wastewater-Based Molecular Surveillance Roll-Outs
    • 4.2.6 AI-Assisted Assay Design Reducing Time-To-Market
  • 4.3 Market Restraints
    • 4.3.1 High Capital & Per-Test Costs Of Advanced MDx
    • 4.3.2 Complex & Evolving Regulatory Frameworks
    • 4.3.3 Enzyme/Oligonucleotide Supply-Chain Volatility
    • 4.3.4 Genomic-Data Privacy & Biosecurity Concerns
  • 4.4 Porter's Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitutes
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Instruments
    • 5.1.2 Reagents & Kits
    • 5.1.3 Software & Services
  • 5.2 By Technology
    • 5.2.1 PCR (Conventional, qPCR, Digital)
    • 5.2.2 Isothermal Amplification (LAMP, INAAT)
    • 5.2.3 Next-Generation Sequencing & Nanopore
    • 5.2.4 CRISPR-based Diagnostics
    • 5.2.5 Mass Spectrometry
    • 5.2.6 Microarrays & Chips
  • 5.3 By Sample Type
    • 5.3.1 Respiratory Swabs
    • 5.3.2 Blood/Plasma
    • 5.3.3 Saliva & Oral Fluids
    • 5.3.4 Stool & GI Samples
    • 5.3.5 Wastewater & Environmental
  • 5.4 By Pathogen Type
    • 5.4.1 Viral
    • 5.4.2 Bacterial
    • 5.4.3 Fungal
    • 5.4.4 Parasitic
    • 5.4.5 Novel / Unknown Pathogens
  • 5.5 By Application
    • 5.5.1 Pathogen Detection
    • 5.5.2 Antimicrobial Resistance (AMR) Testing
    • 5.5.3 Syndromic Panels
    • 5.5.4 Surveillance & Epidemiology
    • 5.5.5 Multiplexed Biothreat Detection
  • 5.6 By End-User
    • 5.6.1 Hospitals & Clinics
    • 5.6.2 Diagnostic Laboratories
    • 5.6.3 Public Health Agencies
    • 5.6.4 Academic & Research Institutes
    • 5.6.5 Others
  • 5.7 Geography
    • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
    • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
    • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 South Korea
    • 5.7.3.5 Australia
    • 5.7.3.6 Rest of Asia-Pacific
    • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
    • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 F. Hoffmann-La Roche Ltd
    • 6.3.2 Abbott Laboratories
    • 6.3.3 Thermo Fisher Scientific Inc.
    • 6.3.4 Danaher Corp. (Cepheid, Beckman Coulter)
    • 6.3.5 Siemens Healthineers AG
    • 6.3.6 Hologic Inc.
    • 6.3.7 QIAGEN N.V.
    • 6.3.8 bioMerieux SA
    • 6.3.9 Illumina Inc.
    • 6.3.10 Seegene Inc.
    • 6.3.11 Luminex (DiaSorin Group)
    • 6.3.12 Oxford Nanopore Technologies
    • 6.3.13 Sherlock Biosciences
    • 6.3.14 Cue Health Inc.
    • 6.3.15 Visby Medical
    • 6.3.16 Lucira Health
    • 6.3.17 T2 Biosystems
    • 6.3.18 PerkinElmer (Revvity)
    • 6.3.19 GenScript Biotech
    • 6.3.20 GenMark Diagnostics (Roche)
    • 6.3.21 Bosch Healthcare Solutions
    • 6.3.22 BGI Genomics
    • 6.3.23 Mylab Discovery Solutions
    • 6.3.24 QuantuMDx

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Molecular Diagnostics For Emerging Infectious Diseases Market Report Scope

According to the scope, emerging infectious diseases (EIDs) are diseases caused by newly discovered pathogens or those that have notably risen in frequency or expanded their geographical distribution, such as COVID-19, antimicrobial resistant tuberculosis and malaria, among others. Molecular diagnostics for emerging infectious diseases utilize advanced technologies to detect, identify, and monitor pathogens at the molecular level, focusing on specific DNA or RNA sequences, such as single nucleotide polymorphisms (SNPs), deletions, rearrangements, insertions, and more, that are associated with various diseases. 

The molecular diagnostics for emerging infectious diseases market is segmented by product type, technology, application, end-user and geography. By product type, the market is segmented into instruments, reagents and kits and other product types. By technology, the market is segmented into in-situ hybridization, chips and microarrays, mass spectrometry, sequencing, polymerase chain reaction (PCR), and other technologies. By application, the market is segmented into pathogen detection, antimicrobial resistance testing, syndromic testing and other applications. By end-user, the market is segmented into hospitals and clinics, diagnostics laboratories, research institutes and other end-user. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.

By Product Type Instruments
Reagents & Kits
Software & Services
By Technology PCR (Conventional, qPCR, Digital)
Isothermal Amplification (LAMP, INAAT)
Next-Generation Sequencing & Nanopore
CRISPR-based Diagnostics
Mass Spectrometry
Microarrays & Chips
By Sample Type Respiratory Swabs
Blood/Plasma
Saliva & Oral Fluids
Stool & GI Samples
Wastewater & Environmental
By Pathogen Type Viral
Bacterial
Fungal
Parasitic
Novel / Unknown Pathogens
By Application Pathogen Detection
Antimicrobial Resistance (AMR) Testing
Syndromic Panels
Surveillance & Epidemiology
Multiplexed Biothreat Detection
By End-User Hospitals & Clinics
Diagnostic Laboratories
Public Health Agencies
Academic & Research Institutes
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Instruments
Reagents & Kits
Software & Services
By Technology
PCR (Conventional, qPCR, Digital)
Isothermal Amplification (LAMP, INAAT)
Next-Generation Sequencing & Nanopore
CRISPR-based Diagnostics
Mass Spectrometry
Microarrays & Chips
By Sample Type
Respiratory Swabs
Blood/Plasma
Saliva & Oral Fluids
Stool & GI Samples
Wastewater & Environmental
By Pathogen Type
Viral
Bacterial
Fungal
Parasitic
Novel / Unknown Pathogens
By Application
Pathogen Detection
Antimicrobial Resistance (AMR) Testing
Syndromic Panels
Surveillance & Epidemiology
Multiplexed Biothreat Detection
By End-User
Hospitals & Clinics
Diagnostic Laboratories
Public Health Agencies
Academic & Research Institutes
Others
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the molecular diagnostics for emerging infectious disease market?

The market is valued at USD 4.06 billion in 2025.

How fast is the market expected to grow?

It is projected to grow at a 5.71% CAGR, reaching USD 5.37 billion by 2030.

Which product segment is expanding the quickest?

Software and services are advancing at a 13.25% CAGR as laboratories adopt integrated platforms.

Which technology is gaining ground on PCR?

CRISPR-based diagnostics are the fastest-growing technology segment at 14.85% CAGR.

Why is Asia-Pacific considered the key growth region?

Government investment in biotech manufacturing and expanding healthcare access underpin a regional CAGR of 10.17%.

What restrains wider adoption of advanced molecular tests?

High per-test costs and evolving regulatory requirements limit rapid deployment, particularly in emerging markets.

Page last updated on: July 16, 2025